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Abstract
Purpose Our insight in the genetics of Hashimoto’s thyroiditis (HT) has become clearer through information provided by 
genome-wide association studies and candidate gene studies, but remains still not fully understood. Our aim was to assess 
how many different genetic risk variants contribute to the development of HT.
Methods 147 HT cases (10.2% men) and 147 controls (13.6% men) were qualified for the analysis. Intrinsic and environ-
mental factors were controlled for. Polymorphisms (SNP) were chosen based on the literature and included markers of the 
genes PTPN22, CTLA4, TG, TPO among others, and of genomic regions pointed by GWAS studies. SNP were typed on a 
microarray. Variants in the HLA-DRB1 gene were identified by Sanger sequencing.
Results Multivariate predisposition to HT was modeled. Based on the investigated group, a model of seven variables was 
obtained. The variability explained by this model was assessed at only 5.4821% (p = 2 × 10−6), which indicates that many 
dozens of factors are required simultaneously to explain HT predisposition.
Conclusions We analyzed genetic regions commonly and most significantly associated with autoimmune thyroid disorders 
in the literature, on a carefully selected cohort. Our results indicated a lack of possibility to predict the risk of HT develop-
ment, even with a multivariate model. We therefore conclude that strong associations of single genetic regions with HT 
should be interpreted with great caution. We believe that a change in the attitude towards genetic association analyses of 
HT predisposition is necessary. Studies including multiple factors simultaneously are needed to unravel the intricacies of 
genetic associations with HT.
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Introduction
Autoimmune responses target the thyroid more frequently 
than any other organ. The term autoimmune thyroid dis-
ease (AITD) refers to the whole spectrum of thyroid auto-
immunity ranging from subclinical disease manifesting by 
the presence of autoantibodies and only slightly elevated 
TSH levels to clinical disease with typical symptoms, high 
TSH and low FT4 and FT3. The prevalence of autoim-
mune thyroid disorders such as Graves’ disease (GD) and 
Hashimoto’s thyroiditis (HT) is estimated to be 5% in the 
overall population [1, 2], but the prevalence of subclinical 
disease manifesting by the production of anti-thyroid anti-
bodies without clinical disease is even higher [3]. Women 
are affected 4–5 times more often than men [3, 4].
HT, also called chronic lymphocytic or autoimmune 
thyroiditis, is part of the spectrum of chronic autoimmune 
thyroid diseases and is associated with various degrees of 
thyroid hypofunction, with lymphocytic infiltration and 
with thyroid autoantibodies production. Thyroid peroxidase 
(TPO) and thyroglobulin (Tg) are the major autoantigens in 
Hashimoto’s disease, but antibodies against those antigens 
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(TPO-Ab and Tg-Ab) occur also in ~ 70% of patients with 
GD. The thyroid-stimulating hormone receptor (TSHR) is 
the major autoantigen in Graves’ disease, but TSHR anti-
bodies may occur also in some patients with Hashimoto’s 
disease [5]. Autoimmune thyroiditis can coexist with other 
endocrine and non-endocrine autoimmune disorders. Auto-
immune polyglandular syndromes (APSs) show a great het-
erogeneity of syndromes and manifest sequentially with a 
large time interval between the occurrence of the first and 
the second glandular autoimmune disease [6]. For example, 
the term “thyrogastric syndrome” defines the association 
between AITD and chronic autoimmune gastritis (CAG), 
and was first described in the early 1960s. More recently, 
this association has been included in polyglandular autoim-
mune syndrome type IIIb, in which autoimmune thyroiditis 
represents the pivotal disorder [7, 8].
The main known susceptibility genes for AITD can be 
divided into thyroid-specific genes and immunoregulatory 
genes [5]. Identified thyroid-specific genes are TSHR and Tg, 
with the TPO gene being of uncertain significance. Single-
nucleotide polymorphisms (SNPs) in TSHR have been spe-
cifically associated with Graves’ disease (but not HT) in the 
Caucasian population [9, 10].
TG is one of the most important candidate genes for 
AITD, since thyroglobulin accounts for about 80% of the 
total thyroid protein content. Even though Tg antibodies are 
not the most sensitive or specific for diagnosing autoimmune 
thyroiditis, Tg has been recognized as a potential early trig-
ger of autoimmune thyroiditis. Supporting a key role for 
Tg in triggering AITD are data showing that TG is a major 
AITD susceptibility gene [11–14].
Apoptosis is proposed as one of the mechanisms which 
could initiate Hashimoto’s thyroiditis. The Fas/Fas ligand 
cascade represents a major pathway-inducing apoptosis. 
Erdogan et al. showed that a gene polymorphism of Fas may 
play a role in the regulation of apoptosis in thyroid autoim-
mune disorders [15].
Variants in immune-modulating genes (such as FOXP3, 
CD25, CD40, CTLA4, and HLA) have also been recog-
nized as risk factors for different autoimmune disorders in 
case–control studies. Polymorphisms in these genes are not 
specific for AITD, as they also confer susceptibility to other 
autoimmune diseases. In a recent study by Houcken et al., 
PTPN22 and CTLA4 polymorphisms have been shown to be 
associated with APS and differentiate between polyglandular 
and monoglandular autoimmunity. The PTPN22 c.1858C>T 
(rs2476601) allele and genotype distribution were markedly 
different between APS, type 1 diabetes, Graves’ disease 
and controls. In addition, SNP CTLA4 CT60 (rs3087243) 
G-allele carriers were more frequently observed in the APS 
(85%) than in the control group (78%) [16].
A lot of work has been published by different authors who 
aimed to correlate HT with the presence of variants in single 
genes. Since a couple of years, it seems, however, clear that 
at the level of SNP association studies we are not able to 
identify single genes which would be crucial for the presence 
of the disease, and researchers tend to the theory that each 
among several genes might have only a small partial effect 
on the disease. In the past years, the complexity of genetic 
factors that influences the development of autoimmunity 
has become increasingly clear through genetic information 
provided by both genome-wide association studies (GWAS) 
and high throughput sequencing. The aim is to understand 
how genetic risk variants contribute to the development of 
the disease. It seems that only the simultaneous presence of 
various genetic and environmental factors altogether may 
overcome a predisposition threshold and lead to the clinical 
outcome of HT [17, 18]. Genetic variants provide the pri-
mary risk for AITD. When this primary genetic risk inter-
acts with environmental factors (e.g. infection, diet, iodine 
exposure), the synergistic effect can trigger the disease (e.g. 
[19]).
In this paper, we aimed to combine multiple genetic 
regions in one study on a carefully selected cohort, and to 
obtain a multivariate model which would allow to assess 
how much of the predisposition to HT can be explained by 
the simultaneous presence of predisposing variants in more 
than one gene. This might also allow to assess the number 
of factors which should be investigated in patients to obtain 
a model which would explain the majority of the disease 
predisposition.
Materials and methods
Compliance with ethical standards
The study was approved by the Bioethical Committee of the 
Jagiellonian University in Krakow (No. KBET/68/B/2011). 
All patients were informed about the reasons of the inves-
tigation and gave their written informed consent prior to 
participation in the study.
Patients
All participants of the study were of Polish origin. Hashi-
moto’s thyroiditis was diagnosed by documented primary 
hypothyroidism requiring thyroid hormone replacement, and 
the presence of autoantibodies to thyroid peroxidase and/or 
anti-Tg antibodies, with or without goiter.
• Inclusion criteria for the HT group: TSH above 4.5 µIU/
ml, the presence of anti-TG and/or anti-TPO antibodies, 
typical for HT ultrasound of the thyroid.
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• Inclusion criteria for controls: the absence of any inclu-
sion criterion for HT, negative history for thyroid dis-
eases among participants and their first degree relatives.
• Exclusion criteria: other thyroid disorders (thyroid nod-
ular and non-nodular goiter, Graves’ disease, thyroid 
inflammation), increased anti-TPO antibodies with nor-
mal TSH levels (only patients with elevated TSH values 
were qualified for the study to obtain a homogeneous 
group for analysis with full disease characteristics), 
increased antibodies against TSH receptor, lack of con-
sent to participate in the study.
None of the participants were related to each other. 
147 HT cases (10.2% men) and 147 controls (13.6% men) 
were qualified for the analysis. These groups were matched 
for gender (p = 0.4717), age (p = 0.9923), marital status 
(p = 0.8148), education (p = 0.1157), monthly income 
(p = 0.7793), and size of the city they live in (p = 0.8535).
Demographic data and environmental factors
Non-genetic factors which might play a role in thyroid 
autoimmunity were assessed by an environmental survey. 
Patients answered questions regarding demographic data 
including gender, age, marital status, completed education 
level, their monthly gross income per person and size of city 
they live in (as a simple measure of air pollution). Ques-
tions about environmental factors included tobacco smok-
ing, alcohol consumption, stress, and a dietary questionnaire. 
Based on the dietary questionnaire, the individual monthly 
iodine, selenium and fiber intake was calculated.
DNA isolation, quantification and quality control
DNA was isolated from whole blood samples collected on 
EDTA, with the NucleoSpin Blood kit (Macherey–Nagel), 
according to the Manufacturer’s protocol. The amount and 
quality of DNA were assessed on NanoDrop 2000 (Thermo 
Fisher Scientific).
Genetic studies
Our study included genomic regions most commonly men-
tioned in connection with AITD in the earlier literature, 
independently on the effect size obtained by the authors. 
The regions under investigation included the genes PTPN22, 
CTLA4, HLA-DRB1, IL10, IL6, TPO, IFIH1, TNF, TG, 
ZFAT, RET, ARID5B, CD40, FOXP3, promoter regions, as 
well as regions typed out for AITD by GWAS on chromo-
somes 12 (gene DCN), 13 (ARGLU1, FAM155A), 14 (TTC9, 
MAP3K9, RGS6, PSEN1), 20 (MAFB, PLCG1, CHD6), and 
X (TNMD, SYTL4, NOX1) [12, 20]. The gene IFIH1 was 
typed out by our team as an additional candidate gene based 
on the literature, although not commonly investigated so far 
in AITD. Analyzed polymorphisms are listed in supplemen-
tary Table 1. Polymorphisms (SNP) in the above-mentioned 
regions were investigated on Illumina HiScan using Illu-
mina’s Golden Gate custom panel, according to the Manu-
facturer’s protocol.
Variants in the HLA-DRB1 gene were identified by Sanger 
sequencing of exon 2 of the gene, which includes most of the 
gene’s heterogeneity. PCR was performed with FirePol poly-
merase (Solis BioDyne), according to the Manufacturer’s 
recommendations, on a BioRad T100 thermocycler. 120 ng 
DNA were used in each 25 µl reaction. Group-specific prim-
ers and PCR conditions were used according to van Dijk 
et al. [21]. Products were visualized electrophoretically, and 
the remaining reaction mixture purified with NucleoSpin 96 
PCR Clean-up (Macherey–Nagel). The products were eluted 
with 70 µl nuclease-free water (Ambion), dried for 2 h at 
75 °C, and pellets were resuspended in 11 µl nuclease-free 
water. The 10 µl sequencing PCR mixture was performed 
with BigDye Terminator v3.1 (ThermoFisher Applied Bio-
systems) and 5× sequencing buffer, 0.7 µl of the appropriate 
10 µM sequencing primer (according to [21]), and 5.3 µl 
of the purified PCR product. The sequencing conditions 
were in agreement with the Manufacturer’s recommenda-
tions, with an annealing temperature of 55 °C. Products were 
purified by ethanol precipitation, and pellets resuspended in 
20 µl nuclease-free water for capillary electrophoresis (ABI 
3500, Applied Biosystems).
Statistical analyses
Statistical analyses were performed in Statistica v12.
Demographic data and environmental factors
For categorical data, the Chi-squared test was applied to 
compare groups. For quantitative and ordinal data, the 
Mann–Whitney test with correction for incontinuity was 
used, with an additional control for tied ranks in case of 
ordinal scale of the data. Results were considered significant 
at α = 0.05.
HLA‑DRB1
Sequencing results were visualized with DNA Baser v4 and 
aligned to the NCBI dbMHC database with use of the SBT 
interface. Association analysis of serotypes and alleles was 
performed with Statistica v12. Alleles were re-coded into 
amino acid sequences to visualize non-synonymous regions.
The CHI^2 test was used for association analysis of 
alleles. Associations were considered significant at α = 0.05. 
Logistic regression was used to reveal a potential pattern 
of the binding cleft, as has been suggested previously [22].
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Polymorphism genotyping
Quality control was performed with the Genotyping module 
of BeadStudio, and based on the GenCall validation. Initial 
laboratory quality assurance (QA) relied on the GenCall 
score, a quality metric indicating the reliability of called 
genotypes that is generated by the BeadStudio software. For 
initial QA, a sample and SNP GenCall_p10 score threshold 
of 0.38 and call rate threshold of 85% were set. All analyzed 
polymorphisms met those criteria. Data were further ana-
lyzed with the tool Plink v1.9 [23]. All SNPs and all patients 
had less than 10% missingness. All polymorphisms under 
investigation were confirmed to meet the Hardy–Weinberg 
equilibrium in the control group (α = 0.05). Association of 
each SNP with HT was determined by Cochran–Armitage 
trend test (Results are shown in supplementary Table 1). The 
most probable mode of inheritance for each SNP was exam-
ined using the permutation procedure implemented in Plink. 
All polymorphisms were included in the further stepwise 
regression analysis, independently of whether they appeared 
to be significantly associated with HT in the standard asso-
ciation analysis.
Genetic model
Stepwise logistic regression was performed to obtain a 
model of genetic regions significantly implicated in the 
predisposition to HT in our sample group. All polymor-
phisms in study were included in the analysis, consider-
ing their mode of inheritance. Also included was pheny-
lalanine at position 67 of the HLA-DRB1 gene, and the 
intrinsic factors sex and age. Logistic regression has been 
chosen because genetic as well as non-genetic factors 
were considered simultaneously. This method also allows 
to automatically exclude redundant variables, which is 
a problem in case of linkage disequilibrium. The good-
ness of fit for the model was assessed by tenfold cross-
validation. The explained predisposition to HT based on 
the obtained model was assessed with the program GCTA 
[24], setting the frequency of HT at 1% [25].
Results
Environmental factors
The HT and control groups were tested for environmental 
factors which are known or suggested to play a role in 
thyroid autoimmunity. Those factors are listed in Table 1.
The HT and control groups did not differ in means of 
the investigated environmental factors.
Table 1  Tested environmental 
factors and p values of the 
appropriate statistical tests as 
stated in the section Methods
HT group Ctrl group p value
Tobacco smoking status—whenever during life (yes/no)
 Yes 30.6% (n = 45) 31.3% (n = 46)
 No 63.3% (n = 93) 60.5% (n = 89) 0.7682
Pack-years of tobacco smoking—median value and interquartile range
2.5 (0.6–6.0) 4.7 (0.7–9.0) 0.4601
Amount of consumed alcohol (g pure ethanol/month)—median value and interquartile range
30 (20–50) 40 (20–60) 0.0728
Amount of stressful life situations
 Hard to tell 10.9% (n = 16) 4.8% (n = 7) 0.5124
 Less than once/month 2.0% (n = 3) 0.7% (n = 1)
 Once/month 1.4% (n = 2) 1.4% (n = 2)
 Several times/month 8.8% (n = 13) 14.3% (n = 21)
 Once/week 4.8% (n = 7) 8.2% (n = 12)
 Several times/week 36.1% (n = 53) 42.9% (n = 63)
 Every day 15.0% (n = 22) 8.8% (n = 13)
 Several times/day 19.7% (n = 29) 17.0% (n = 25)
Iodine intake (µg/day)—median value and interquartile range
272.4 (236.8–324.1) 271.6 (231.2–323.4) 0.7631
Selenium intake (µg/day)—median value and interquartile range
116.8 (83.9–162.8) 121.3 (89.9–157.8) 0.7008
Fiber intake (g/day)—median value and interquartile range
38.6 (30.3–51.6) 39.5 (30.5–51.1) 0.6773
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HLA‑DRB1
The percentages of different HLA-DRB alleles were in 
agreement with frequencies stated at http://www.allel efreq 
uenci es.net for the Polish population (n = 20,653 alleles) 
(data not shown).
Stepwise logistic regression analysis which included 
only amino acid positions suggested by Menconi et al. [22], 
revealed a weak correlation between Tyr-30 and Arg-71 with 
HT. The only allele significantly associated with HT in our 
study was HLA-DRB1*11:04, but only as long as no correc-
tion for multiple comparisons was applied (p = 0.0381). This 
allele is characterized by the presence of Tyr-30 and Arg-71. 
Arginine at position 71 has, however, been previously shown 
by Menconi et al. to play a protective role [22].
If all non-synonymous amino acid positions were ana-
lyzed, only phenylalanine at position 67 turned out to be sig-
nificantly associated with HT in our study group (p = 0.0060, 
OR = 1.675, 95% CI 1.161–2.417).
Genotyping results
Among 37 typed polymorphisms, 8 (21.6%) were signifi-
cantly associated with HT in the single variant associa-
tion analysis at α = 0.05. Those were PTPN22 rs3811021 
(p = 0.0333), PTPN22 rs2476599 (p = 0.0027), TPO pro-
moter region rs11211645 (p = 0.0127), IFIH1 rs1990760 
(p = 0.0281), intergenic region at chr. 13q33.3 (p = 0.0449), 
RGS6 rs2074953 (p = 0.0047), TNMD rs5966709 
(p = 0.0023), and NOX1 rs5921679 (p = 0.0375).
However, after Bonferroni correction, none of the poly-
morphisms itself was significantly associated with HT.
Results of single variant association analyses for all tested 
SNPs are presented in Supplementary Table 1.
Stepwise logistic regression model
The multivariate predisposition to HT was modeled. Based 
on the investigated group, a model of 7 variables was 
obtained, which included polymorphisms in the genes HLA-
DRB1 on chromosome 6, PTPN22 on chr. 1, NOX1 on chr. 
X, a polymorphism downstream from FAM155A on chr. 13, 
IFIH1 on chr. 2, RGS6 on chr. 14 and TNMD on chr. X, 
all under the dominant inheritance model. The multivariate 
model is summarized in Table 2.
Regression fitting parameters for the model were as fol-
lows. Wald’s test for the model: p = 3 × 10−6, Hosmer–Leme-
show test: p = 0.9490. AUC values were 0.730 ± 0.029 and 
0.688 ± 0.031 for the basic training dataset and tenfold cross-
validation, respectively.
The variability explained by the obtained model was 
assessed at 5.4821% (p = 2 × 10−6), which can be inter-
preted in that almost 5.5% of the predisposition to HT can 
be explained by the obtained model in the investigated group 
of patients and cases.
The predictive ability of the model was 65.3 and 64.6% 
for affected and unaffected, respectively.
Discussion
In their work, Menconi et al. typed amino acids Tyr-26, Tyr-
30, Gln-70, Lys-71 and Arg-74 as strongly associated with 
HT, with the strongest effect observed for Lys-71 [22]. Such 
a pattern is present in the allele HLA-DRB1*03:01, which 
was the only significantly associated allele in their study. In 
our study, no such correlation could be confirmed. The only 
significant association for HLA-DRB1 found in our study 
concerned position 67 with phenylalanine. Other hydropho-
bic and non-polar amino acids (leucine, isoleucine) at this 
position have been previously correlated with rheumatoid 
arthritis [26, 27], and amino acid region 67–74 is the most 
commonly associated with this and other autoimmune dis-
orders [28].
According to Menconi et al. [22], arginine at position 71 
should have a strong protective effect, while in our study 
this amino acid was present in the only HT-associated allele 
HLA-DRB1*11:04. It should be noted that both studies, the 
Table 2  Multivariate HT 
predisposition model
Associations were considered significant at α = 0.05
p value from logistic regression, OR odds ratio, CI confidence interval
Variable Gene or region p OR (95% CI)
Intercept – 0.2244 0.617 (0.283–1.345)
rs17886918_T HLA-DRB1, Phe-67 0.0217* 1.889 (1.097–3.253)
rs3811021_G PTPN22, untranslated region 0.0200* 1.946 (1.110–3.409)
rs5921679_A NOX1, intronic variant 0.0007* 2.593 (1.495–4.498)
rs2769917_A 3′ from FAM155A 0.0210* 2.647 (1.158–6.053)
rs3747517_A IFIH1, His843Arg 0.0117* 2.043 (1.172–3.560)
rs2074953_G RGS6, intronic variant 0.0053* 0.462 (0.269–0.795)
rs5966709_A TNMD, intronic variant 0.0077* 0.454 (0.254–0.811)
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one of Menconi et al. [22], as well as our own, are based 
on very limited numbers of investigated patients and con-
trols: in the cited paper 94 patients and 153 controls were 
studied. In our study, we analyzed 147 cases and 147 con-
trols. For a region as heterogeneous as the genomic locus 
which includes the gene HLA-DRB1, accidental correlations 
are very likely to be obtained in small sample groups. The 
small sample number combined with slight differences in the 
recruitment parameters in both studies might have generated 
the observed discrepancies.
We obtained a model of seven variables (genomic 
regions) that have the greatest combined effect on HT pres-
ence in our study group. HLA-DRB1 and PTPN22 are genes 
involved in the immune response, which have been com-
monly associated with HT and other autoimmune disorders 
in the literature. Houcken et al. showed that the genotype 
distribution of a PTPN22 polymorphism is markedly dif-
ferent between APS, type 1 diabetes, Graves’ disease and 
controls [16]. IFIH1 is another immune-regulatory gene, 
which has been included in our study as a new candidate 
gene based on literature. The remaining SNPs in the model 
are markers of regions which have been typed by GWAS in 
previously published papers. While rs2769917 is a marker of 
a region correlated with HT, rs5921679 (NOX1), rs2074953 
(RGS6) and rs5966709 (TNMD) are located in regions which 
have been previously correlated specifically with GD, but 
not with HT [12, 20].
Of course, the number of variables is limited by the 
number of study participants. It seems probable that the 
polymorphisms included in the model, or even the genes 
in the model, would differ if another population had been 
investigated. It can also not be ruled out that non-genetic 
factors or gene–gene or gene–environment interactions may 
be necessarily considered in a genetic model to improve its 
parameters. In our study, environmental factors have been 
controlled for before modelling, and thus did not appear sig-
nificant enough to become included in the model.
Independently of the above considerations, we were able 
to type 7 most important polymorphisms for HT, in well-
defined groups of cases and controls. Each of these genetic 
regions has been claimed in the literature to be of signifi-
cant importance for HT development, and no other better 
susceptibility markers for this disease have been identified 
so far. Still, their combined effect accounts for only a very 
small percentage of the observed variance. The obtained 
seven-variable model was able to explain less than 5.5% 
of the study group variance (i.e. HT predisposition). This 
seems quite reliable when compared to about 20% variance 
explained by a 27-loci model for vitiligo, published by Jin 
et al. [29]. It, however, also means that a good predictive HT 
model should include dozens or even hundreds of different 
parameters. This, in turn, is possible only with extremely 
large study groups.
We want to emphasize in this paper that each single 
investigation on single genetic regions in case of diseases 
of complex etiology should be interpreted with great cau-
tion. Pathogenically, multifactorial diseases such as HT 
require complex analyses during genetic testing. We think, 
at the present state, that there is little need to undertake 
new association studies on single well-documented genes 
which have been previously investigated extensively. 
Based on our results, we expect that at least a few dozen 
genetic regions affect the predisposition to HT. Testing an 
appropriately large group would reveal many more vari-
ables and might allow to generate a model which would 
apply to new patients. We therefore believe that further 
research should be undertaken that focus not only on sin-
gle genetic factors, but also on the impact of the simul-
taneous presence of different genetic variants and envi-
ronmental factors, and possibly also interactions between 
them. Unfortunately, so far, insufficient attention has usu-
ally been paid to environmental and intrinsic factors in 
genetic studies on HT predisposition, while differences 
between the tested and control group may impact genetic 
results in an unpredictable way.
Our results also stress how different results can be 
obtained depending on inclusion and exclusion crite-
ria used in different studies. For example, there is still 
no agreement of whether patients with positive thy-
roid autoantibodies but no clinical symptoms should 
be included in the study as the case group or excluded 
from further analysis. The decision of the investigators 
regarding this issue may, however, have an impact on the 
obtained results. This can be clearly seen on the example 
of HLA-DRB discussed above, but also in the fact that 
some of the significantly associated regions in our model 
have previously been shown by others to be specifically 
associated only with GD. HT groups are usually more 
heterogeneous than GD groups, thus specific effects are 
supposed to be weaker than for GD patients. It therefore 
seems more probable to oversee significant but relatively 
weak effects for HT, especially when there is a clinically 
heterogeneous population under investigation. All this 
makes it difficult to compare results of different studies, 
and also to perform literature-based meta-analyses.
Our final model included only genetic factors, while 
a number of environmental factors were controlled for 
during recruitment of participants. It has previously been 
shown that environmental factors as well play a signifi-
cant role for AITD risk [30, 31]. Those factors still remain 
mainly unknown, it should, however, be considered in 
future studies to include environmental parameters in 
analyses, or at least try to control known environmental 
factors, when working on HT predisposition models.
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Conclusions
Hashimoto’s thyroiditis (as probably most autoimmune 
disorders) is a disease with complex background, with 
dozens or hundreds of different factors influencing the risk 
of each individual case. These factors might differ between 
individuals. To obtain a good predictive model, studies 
on this topic should focus on the simultaneous analysis of 
multiple genetic and environmental factors.
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